Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.
J Drugs Dermatol
; 21(2): 122-126, 2022 Feb 01.
Article
en En
| MEDLINE
| ID: mdl-35133112
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Ustekinumab
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article